Bio-Path Holdings, Inc. (BPTH)

USD 0.67

(-6.95%)

Market Cap (In USD)

2.88 Million

Revenue (In USD)

-

Net Income (In USD)

-16.07 Million

Avg. Volume

346.48 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.59-12.0
PE
-
EPS
-
Beta Value
0.222
ISIN
US09057N3008
CUSIP
09057N300
CIK
1133818
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Peter H. Nielsen MBA
Employee Count
-
Website
https://www.biopathholdings.com
Ipo Date
2008-03-04
Details
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 that is in preclinical stage for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and prexigebersen-A for various solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas.